Autres langues Senhwa Biosciences, Inc.

Actions

6492

TW0006492002

Cours en clôture Taipei Exchange Autres places de cotation 00:00:00 15/05/2024			Varia. 5j.	Varia. 1 janv.
41,7 ^TWD	+0,24%		+0,24%	-18,07%

20/03	Senhwa Biosciences annonce que le premier patient a été traité dans le cadre de l'étude de phase II sur le silmitasertib chez des patients atteints de pneumonie communautaire associée à une infection virale à Taïwan	CI
14/03	Senhwa Biosciences, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Senhwa Biosciences Announces First Patient Dosed in the Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection in Taiwan	20/03
Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Senhwa Biosciences, Inc. Decides to Early Terminate the Phase II study of Silmitasertib to treat hospitalized patients with COVID-19	05/01
Senhwa Biosciences Receives Taiwan FDA IND Approval for Phase Ii Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection	26/12
Basal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	20/12
Senhwa Biosciences Received US FDA IND Approval for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection	22/11
Senhwa Biosciences Announces First Patient Successfully Dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19	10/11
Senhwa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19	09/11
Senhwa Biosciences Announces Investigational New Drug Submission to U.S. Food and Drug Administration for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection	19/10/23
Senhwa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23
Senhwa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23/05/23
Senhwa Biosciences Receives Taiwan Fda Ind Approval for Phase II Study of Silmitasertib in Patients with Moderate to Severe Covid-19	28/04/23
Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23
Senhwa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/11/22
Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer	31/10/22
Senhwa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22
Senhwa Biosciences, Inc. Pindnarulex in Combination Study with Pfizer's Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC	06/06/22
Senhwa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	12/05/22
Senhwa Biosciences, Inc. Presents Positive Initial Data from Phase 1 Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma at 2022 AAD Annual Meeting	28/03/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Senhwa Biosciences, Inc.

Actions

6492

TW0006492002

Autres langues

Filtres